Description
In the journey of weight loss, everyone eventually reaches a plateau, even when using newer GLP-1 receptor agonists like semaglutide (Wegovy) and tirzepatide (Zepbound). This phase is where the body finds a new set point and weight. During this plateau, some individuals may experience a gradual increase in appetite or “food noise”, while others can maintain their current state. Other metabolic markers like blood pressure and A1c, stabilize or only fluctuate slightly.
It’s important to remember that everyone will plateau. And it’s impossible to predict the specific timing, percentage of weight loss, or speed at which a person will reach their plateau when they start a GLP-1 agonist.
What do the studies say? Clinical studies show that this plateau typically occurs a little over a year (about 60 weeks) into treatment with semaglutide. However, a common myth is that if you hit a weight loss plateau while using these medications, it means they are no longer working. And this myth can lead to unnecessary frustration and discontinuation of treatment.
I like to remind patients that reaching a new set point is a common phenomenon in many health conditions. For example, a patient on blood pressure medication will not become hypotensive indefinitely, and similarly, blood glucose levels will not decrease indefinitely with diabetes medications. So it should be no surprise that you won’t lose weight indefinitely while taking a GLP-1 agonist. This evolutionary mechanism is essential for protecting the body against extremes.
In this podcast, we’ll talk about strategies to move past the weight loss plateau if you haven’t yet met your weight loss goal.
Understanding Weight Loss Plateaus A weight loss plateau occurs when you stop losing weight despite maintaining your diet and exercise routine. This is a common experience for many people on a weight loss journey, regardless of whether they are using GLP-1 agonists or not. Several factors can contribute to a plateau:
Metabolic Adaptation: As you lose weight, your metabolism slows down because your body requires fewer calories to maintain a smaller body size.
Reduced Caloric Deficit: You may lose weight quickly initially, but as you progress, the caloric deficit narrows, slowing down weight loss.
Water Retention and Muscle Gain: Changes in water balance and muscle mass can temporarily affect weight measurements.
Behavioral Factors: Over time, adherence to diet and exercise routines can wane, impacting progress.
Why GLP-1 Agonists Are Still Effective During a Plateau GLP-1 agonists continue to work by regulating appetite, improving insulin sensitivity, and promoting satiety. These mechanisms support long-term weight management and metabolic health, even if weight loss temporarily stalls. Plateaus do not negate these ongoing health benefits.
Strategies to Overcome a Weight Loss Plateau Reevaluate Your Caloric Intake: As you lose weight, your caloric needs decrease. Adjust your daily caloric intake to reflect your new body weight and activity level. Consider consulting a dietitian to ensure your nutrition plan is optimal.
Increase Physical Activity: Incorporate more physical activity into your routine. Adding strength training can help build muscle, which can boost metabolism. When we lose weight, we lose both muscle and fat. Physical activity is crucial during a weight loss journey because it helps preserve lean muscle mass and boosts metabolism, ensuring that the weight loss is primarily fat rather than muscle.
Monitor Macronutrient Balance: Ensure you are consuming the right balance of proteins, fats, and carbohydrates. Protein, in particular, can help preserve muscle mass and promote satiety.
Stay Hydrated: Proper hydration is essential for overall health and can aid in weight loss. Sometimes, perceived plateaus are due to water retention, which can be mitigated by drinking adequate water.
Manage Stress and Sleep: Stress and poor slee
Imagine a treatment that not only helps manage diabetes but also holds the potential to reverse kidney failure — what was once thought to be impossible. The recent FLOW study has remarkable groundbreaking evidence that GLP-1 receptor agonists can significantly improve kidney function in chronic...
Published 10/29/24
Have you heard of fatty liver disease? Well, fatty liver disease is just what it sounds like—it's when fat builds up in the liver and starts causing issues. The official name for it is “nonalcoholic fatty liver disease,” or NAFLD for short. Now, if that fat buildup leads to inflammation, it’s...
Published 10/17/24